ODI Pharma AB announces strategic market entry with initial shipment to Switzerland

ODI Pharma AB (“ODI” or the “Company”) is pleased to announce the first delivery of cannabis products to the leading medical cannabis provider in Switzerland. The delivery marks a symbolic milestone in ODI's market expansion efforts as it is the first delivery to the Swiss market. The delivery, which is facilitated through ODI’s Swiss subsidiary, is less significant in terms of economic value but more important from a strategic point of view.

Exploration of Other European Markets

ODI Pharma is consolidating its position in the Eastern European medical cannabis market and is exploring additional European markets. This initiative is in line with ODI's goal to widen its market footprint and adapt to changing market dynamics. This order to the Swiss market, with products already shipped, represents a cautious yet forward-looking step towards a wider market engagement.
ODI's entry into Switzerland and other European markets signifies a commitment to strategic growth. By venturing into new territories, ODI aims to contribute to the evolving European medical cannabis landscape, leveraging its expertise to meet industry needs across the continent. This approach exemplifies ODI's optimism for the future, aiming to deliver value to patients and stakeholders while navigating the complexities of international markets.

For more information on ODI Pharma, please contact:
Volker Wiederrich, Chairman, ODI Pharma AB
E-mail: [email protected]
 

ODI Pharma AB
ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.